Latest News

January 25, 2016

ITN's LEAP and HALT-MS Trials Included in NIAID's 15 "Selected Research Advances for 2015"

The ITN’s LEAP and HALT-MS trials were two of the 15 highlighted topics in NIAID’s selected research advances for 2015.  In his opening remarks, NIAID Director Tony Fauci explains that this selection includes “notable scientific advances made by NIAID researchers and NIAID-funded scientists” and “are representative of how public investment in biomedical research drives scientific progress and benefits human health.”LEAP was the first large, well-powered clinical trial to conclusively demonstrate the benefits of early peanut consumption in

January 7, 2016

ITN's LEAP Study Manuscript has been Selected as One of the "Most Notable Articles of 2015"

The ITN's LEAP study manuscript was selected by the New England Journal of Medicine as one of the most notable articles of 2015. The LEAP study provided conclusive evidence that early consumption of peanut by high-risk infants prevents the development of peanut allergy later on.In the introductory letter from NEJM Editor-in-Chief, Jeffrey Drazen, he notes that “this digital collection represents the cream of the crop, the dozen studies from 2015 that we think will have the biggest influence on medicine.”

December 4, 2015

ITN Helped Support Mechanistic Studies in New T1D Immunotherapy Publication

 A manuscript published in the November 25, 2015 online issue of Science Translational Medicine reported no serious adverse reactions in the first phase 1 safety trial of a new immunotherapy approach investigating regulatory T cells (Tregs) for the treatment of type 1 diabetes (T1D). The clinical study was conducted at UCSF by Stephen E. Gitelman, MD, and Kevan C. Herold, MD, and was designed and analyzed by Jeffrey A. Bluestone, PhD.

November 10, 2015

Request for Proposals: Clinical Trials of Immune Tolerance in Solid Organ Transplantation

The ITN is currently seeking proposals for clinical tolerance trials in solid organ transplantation. We are interested in trials using cell therapy to acheive tolerance in solid organ (liver and kidney) transplant. The ideal proposal should have a testable mechanism of tolerance induction and a strategy for assays to investigate this mechanism.Full details are included in the RFP.

October 27, 2015

ITN opens the OPTIMAL study for liver transplant recipients

The Immune Tolerance Network (ITN) opened the OPTIMAL Study for liver transplant recipients at the first clinical site, the University of California, San Francisco on Monday, October 26, 2015. The OPTIMAL Study (Operational Tolerance Biomarkers of Immune Senescence and Lymphocyte Exhaustion Following Adult Liver Transplantation) will enroll 60 adult liver transplant recipients.

October 22, 2015

New Publication: B-cell signature in tolerant kidney transplant recipients

A potential biomarker of tolerance in kidney transplant recipients was found to be stable for up to three years in a cohort of 32 operationally tolerant kidney recipients from the ITN’s FACTOR study. The signature is characterized by the increased expression of two genes associated with B cells, suggesting a potential role of B cells in regulating the immune response to the kidney.

October 14, 2015

IMPACT study for peanut allergy completes enrollment

The Immune Tolerance Network (ITN) completed enrollment this week for the IMPACT Study in peanut allergy. There are 144 participants enrolled in the IMPACT Study (Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children), which tests whether giving increasing doses of peanut protein (oral immunotherapy) over a two-year period can induce desensitization to peanut.  The trial will also address whether extended oral immunotherapy can create long-lasting tolerance to peanut.

October 7, 2015

New Publication: Long-term follow-up of islet transplant protocol

Long-term safety and efficacy results of the Edmonton Protocol for islet transplantation were reported October 3, 2015 in the American Journal of Transplantation. Data from the Immune Tolerance Network’s (ITN) EXIIST Study (Extended Immunosuppression in Islet Transplantation), led by Dr.

September 17, 2015

Drs. Nepom and Corren Discuss the CATNIP Study with Radio Pet Lady, Tracie Hotchner

Jerry Nepom, MD, PhD, director of the Immune Tolerance Network (ITN) and Jonathan Corren, MD, protocol chair for the ITN’s CATNIP Study, were recently interviewed by Tracie Hotchner from the Radio Pet Lady Network.As part of the interview, Dr. Nepom discussed some specifics about the CATNIP study, including who might be eligible to participate, why the ITN is conducting this study and how this clinical trial as a proof of concept trial has the potential to advance medical research far beyond cat allergy treatments.

September 15, 2015

American Academy of Pediatrics Endorses Early Peanut Introduction Based on ITN’s LEAP Study

On August, 31, 2015, interim guidance on the early introduction of peanut for the prevention of peanut allergy based on ITN’s “Learning Early About Peanut Allergy” LEAP Study was published in The Journal of Allergy and Clinical Immunology.